Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Bianchi

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapyJosé Baselga, Karen A Gelmon, Shailendra Verma, et al.
The British Journal of Surgery|March 5, 2025
Axillary surgery versus no-axillary staging in T1N0 breast cancer: 20-year follow-up of the INT 09/98 randomized clinical trialRoberto Agresti, Marco Sandri, Giuseppe Capri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancerLuca Gianni, Anna Lladó, Giulia Bianchi, et al.
Medicina (Kaunas, Lithuania)|January 25, 2025
Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and ManagementGiovanni Paolino, Mario Valenti, Andrea Carugno, et al.
Journal of the Peripheral Nervous System : JPNS|September 18, 2007
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity ScaleGuido Cavaletti, Barbara Frigeni, Francesca Lanzani, et al.
Annals of Surgical Oncology|November 18, 2025
Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional StudyGabriele Martelli, Francesco Barretta, Carlo Muzi, et al.
Scientific Reports|June 9, 2018
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancerClaudio Vernieri, Alessia Mennitto, Michele Prisciandaro, et al.
International Journal of Environmental Research and Public Health|March 4, 2020
Long-Term Subjective Outcomes of Barbed Reposition Pharyngoplasty for Obstructive Sleep Apnea Syndrome TreatmentGiannicola Iannella, Bianca Vallicelli, Giuseppe Magliulo, et al.
Clinical Breast Cancer|January 13, 2019
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety ProfilesClaudio Vernieri, Michele Prisciandaro, Monica Milano, et al.
Radiation Oncology (London, England)|March 24, 2018
Partial breast irradiation with CyberKnife after breast conserving surgery: a pilot study in early breast cancerLaura Lozza, Laura Fariselli, Marco Sandri, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapyJosé Baselga, Karen A Gelmon, Shailendra Verma, et al.
The British Journal of Surgery|March 5, 2025
Axillary surgery versus no-axillary staging in T1N0 breast cancer: 20-year follow-up of the INT 09/98 randomized clinical trialRoberto Agresti, Marco Sandri, Giuseppe Capri, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2010
Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancerLuca Gianni, Anna Lladó, Giulia Bianchi, et al.
Medicina (Kaunas, Lithuania)|January 25, 2025
Serum Lipids Alterations in Patients Under Systemic JAK Inhibitors Treatments in Dermatology: Clinical Aspects and ManagementGiovanni Paolino, Mario Valenti, Andrea Carugno, et al.
Journal of the Peripheral Nervous System : JPNS|September 18, 2007
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity ScaleGuido Cavaletti, Barbara Frigeni, Francesca Lanzani, et al.
Annals of Surgical Oncology|November 18, 2025
Sentinel Node Biopsy Alone Versus Sentinel Node Biopsy Plus Axillary Dissection in cT2 cN0/1 Breast Cancer After Neoadjuvant Chemotherapy: 15-Year Results of a Prospective Interventional StudyGabriele Martelli, Francesco Barretta, Carlo Muzi, et al.
Scientific Reports|June 9, 2018
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancerClaudio Vernieri, Alessia Mennitto, Michele Prisciandaro, et al.
International Journal of Environmental Research and Public Health|March 4, 2020
Long-Term Subjective Outcomes of Barbed Reposition Pharyngoplasty for Obstructive Sleep Apnea Syndrome TreatmentGiannicola Iannella, Bianca Vallicelli, Giuseppe Magliulo, et al.
Clinical Breast Cancer|January 13, 2019
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety ProfilesClaudio Vernieri, Michele Prisciandaro, Monica Milano, et al.
Radiation Oncology (London, England)|March 24, 2018
Partial breast irradiation with CyberKnife after breast conserving surgery: a pilot study in early breast cancerLaura Lozza, Laura Fariselli, Marco Sandri, et al.
Pageof 7